MCL1 and T-cell non-Hodgkin lymphoma: In order to determine the extent to which MCL-1 loss is a significant mechanism of action for CDK9 antagonism in the T-cell lymphomas, BH3 profiling was performed and cell lines stratified by MCL-1 dependence (Fig. 2A).